References - Shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/19435/14/14_references.… · References 1. World Health Organization. The world Health Report 1997. Geneva: World

References

References

1. World Health Organization. The world Health Report 1997. Geneva: World Health Organization, (1997).

2. D' Alessandro U, Olaleye BO, Mcguire W, LangerockP, Bennett S, Aikins MK, Thomson MC, et al. (1995) Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bed programme. Lancet. 345:479-483.

3. Bruce Chwatt, LJ. (1988) History of malaria from prehistory to eradication, p.1-59. In W.Wemsdorfer and I. Mcgregor (ed.), Malaria, Principles and Practice of Malariology, vol.1. Churchill Livingstone, Edinburgh, United Kingdom.

4. Malaria fact sheet WHO. (2002) Maryland Department of Health & Mental Hygiene Epidemiology & Disease Control Program.

5. Moulineaux, L. (1988) The epidemiology of human malaria as an explanation of its distribution, including some implications for its control. In W.Wemsdorfer and I. Mcgregor (ed.), Malaria, Principles and Practice of Malariology, vol.1. Churchill Livingstone, Edinburgh, United Kingdom. 2,913-999.

6. Gilles, HM and Warell, DA. (Eds)(1993). Bruce Chwatt's essential malariology. Boston: Edward Arnold.

7. Greenwood, BM, Marsh, K, and Snow, R. (1991) Why do some African children develop severe malaria? Parasitol. Today, 8, 239-242.

8. Marsh K. (1992) Malaria -a neglected disease? Parasitol. , 104. S53-69.

9. Trape , JF, Rogier, C. et.al.( 1994) The Dielmo project: a longitudinal study of natural malaria infection and the mechanism of protective immunity in a community living in a holo-endemic area of Senegal. Am. J. Trop. Med. Hyg., 51(2):123-137.

10. Brewster DR, Kwaitkowski D, White NJ. (1990) Neurological sequale of cerebral malaria in children. Lancet. 336:1039-1043.

11. Gupta S, Day KP. (1994) A theoretical framework of immuno­epidemiology of Plasmodium Jalciparum malaria. Parasite Immunol. 16(7):361-370.

12. Maitland K, Williams TN, Bennett S, Newbold CI, Peto TE, Viji J, Timothy R, Clegg JB, Weatherall DJ, Bowden DK. (1996) The interaction between Plasmodium Jalciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans. R. Soc. Trop. Med. Hyg. 90(6):614-20.

133

References

13. Allen SJ, O'Donnell A, Alexander ND, Alpers MP, Peto TE, Clegg JB, Weatherall DJ. (1997) Alpha ± Thalassemia protects children against disease caused by other infections as well as malaria. Proc. Natl. Acad. Sci. USA. 94(26):14736-41.

14. Haldane JBS. (1948) The rate of mutation of human genes. Hered. 35 (suppl),267-273.

15. Hill AV, Allsopp CE, Kwiatkowski D, AnsteyNM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM. (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature. 352 (6336):595-600.

16. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend AR, et al. (1992) Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature. 360(6403):434-9.

17. Genton B, al-Yarnan F, Mgone CS, Alexander N, Paniu MM, Alpers MP, Mokela D. (1995) Ovalocytosis and cerebral malaria. Nature. 378 (6557):564-5.

18. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. (1994) Variation in the TNF-a promoter region associated with susceptibility to cerebral malaria. Nature. 371(6497):508-10

19. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ (eds). Malaria: Obstacles and opportunities. Washington, DC: National Academy Press, 1991.

20. Shepard DS, Ettling MB, Brinkmann U, Sauerbom R. (1991) The economic cost of malaria in Africa. Trop. Med. Parasitol. 42(3): 199-203.

21. Miller LH, Hoffman SL. (1998) Research toward vaccines against malaria. Nat. Med. 4 (5 Suppl):520-4.

22. White N. (1999) Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B. Bioi. Sci. 354(1384):739-49

23 Krotoski W A, Collins WE, Bray RS, Garnharn PC, Cogswell FB, Gwadz RW, Killick-Kendrick R, Wolf R, Sinden R, Koontz LC, Stanfill PS. (1982) Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am. J. Trop. Med. Hyg. 31(6):1291-3.

24. Krotoski W A, Garnharn PC, Bray RS, Krotoski DM, Killick-Kendrick R, Draper CC, Targett GA, Guy MW. (1982) Observations on early and late post-sporozoite tissue stages in primate malaria. 1. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to

134

References

detect hepatic forms within the first 24 hours after infection. Am. J. Trop. Med. Hyg. 31(1):24-35.

25. White NJ. (1998) Drug resistance in malaria. Br. Med. Bull. 54(3):703-15.

26. Sajid M, McKerrow JH. (2002) Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120(1):1-21.

27. Barrett AJ, Rawlings ND, Woessner JF, eds. (1998). Handbook of proteolytic Enzymes. NewY ork: Academic.

28. Wu Y, Wang X, Liu X, Wang Y. (2003) Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite. Genome Res. 13(4):601-16.

29. Olaya P, Wasserman M. (1991) Effect of calpain inhibitors on the invasion of human erythrocytes by the parasite Plasmodium Jalciparum. Biochim. Biophys. Acta. 1096(3):217-21.

30. Southan C. (2001) A genomic perspective on human proteases as drug targets. Drug Discov. Today. 6(13):681-688.

31. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y, Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ. (2002) A proteomic view of the Plasmodium falciparum life cycle. Nature. 419(6906):520-6.

32. Gero AM, O'Sullivan WJ. (1990) Purines and pyrimidines in malarial parasites. Blood Cells. 16(2-3):467-84:485-98.

33. Subbayya IN, Ray SS, Balaram P, Balaram H. (1997) Metabolic enzymes as potential drug targets in Plasmodium Jalciparum. Indian J. Med. Res. 106:79-94.

34. Surolia N, Surolia A. (2001) Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium Jalciparum. Nat. Med. 7(2):167-73. Erratum m: Nat. Med. (2001):7(5);636.

35. Kapoor M, Dar MJ, Surolia A, Surolia N. (2001) Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium Jalciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 289(4):832-7.

36. Peterson DS, Milhous WK, Wellems TE. (1990) Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium Jalciparum malaria. Proc. Natl. Acad. Sci. USA. 87(8):3018-22.

135

References

37. Shennan IW. (1977) Amino acid metabolism and protein synthesis in malarial parasites. Bull. World Health Organ. 55(2-3):265-76.

38. Shennan IW, Ting IP. (1966) Carbon dioxide fixation in malaria (Plasmodium lophurae). Nature. 212(68):1387-8.

39. Stryer L. Biochemistry. New York: WH Freeman;(1988): 143-176.

40. Loria P, Miller S, Foley M, Tilley L. (1999) Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem. J. 339 (Pt 2): 363-70.

41. McConnick GJ. (1970) Amino acid transport and incorporation in red blood cells of nonnal and Plasmodium knowlesi infected rhesus monkeys. Exp. Parasitol. 27(1):143-9.

42. Shennan IW, Tanigoshi L. (1974) Incorporation of 14C-amino acids by malarial plasmodia (Plasmodium lophurae). VI. Changes in the kinetic constants of amino acid transport during infection. Exp. Parasitol. 35(3):369-73.

43. Geary TG, Divo AA, Jensen JB. (1985) Nutritional requirements of Plasmodium falciparum in culture. II. Effects of antimetabolites in a semi­defined medium. J. Protozool. 32(1):65-9.

44. Polet H, Conrad ME. (1968) Malaria: extracellular amino acid requirements for in vitro growth of erythrocytic fonns of Plasmodium knowlesi. Proc. Soc. Exp. BioI. Med. 127(1):251-3.

45. Francis SE, Gluzman IY, Oksman A, Knickerbocker A, Mueller R, Bryant ML, Shennan DR, Russell DG, Goldberg DE. (1994) Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 13(2):306-17.

46. Bailly E, Jambou R, Savel J, Jaureguiberry G. (1992) Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor). J. Protozool. 39( 5):593-9.

47. Rosenthal PJ, Olson JE, Lee GK, Palmer JT, Klaus JL, Rasnick D. (1996) Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother. 40(7):1600-3.

48. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. (1991) Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J. Clin. Invest. 88(5):1467-72.

49. Rosenthal PJ. (1995) Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp. Parasitol. 80(2):272-81.

136

References

50. Rosenthal PJ, McKerrow JH, Rasnick D, Leech JH. (1989) Plasmodium Jalciparum: inhibitors of lysosomal cysteine proteinases inhibit a trophozoite proteinase and block parasite development. Mol. Biochem. Parasitol. 35(2):177-83.

51. Wilson RI, Pasvol G, Weatherall DJ. (1977) Invasion and growth of Plasmodium Jalciparum in different types of human erythrocyte. Bull. World Health. Organ. 55(2-3):179-186

52. Pasvol G, Weatherall DJ, Wilson RI. (1977) Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium Jalciparum. Nature. 270(5633): 171-3.

53. Geary TG, Delaney EJ, Klotz 1M, Jensen JB. (1983) Inhibition of the growth of Plasmodium Jalciparum in vitro by covalent modification of hemoglobin. Mol. Biochem. Parasitol. 9(1 ):59-72.

54. Ginsburg H. (1990) Some reflections concerning host erythrocyte-malarial parasite interrelationships. Blood Cells. 16(2-3):225-35.

55. Desai SA, Krogstad DJ, McCleskey EW. (1993) A nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature. 362(6421):643-6.

56. Krogstad DJ, Schlesinger PH, Gluzman IY. (1985) Antimalarials increase vesicle pH in PlasmodiumJalciparum. J. Cell BioI. 101(6):2302-9.

57. Yayon A, Cabantchik ZI, Ginsburg H. (1984) Identification of the acidic compartment of Plasmodium Jalciparum infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 3(11 ):2695-700.

58. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. (2002) Four plasmepsins are active in the Plasmodium Jalciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. U SA. 99(2):990-5.

59. Gavigan CS, Dalton JP, Bell A. (2001) The role of aminopeptidases in haemoglobin degradation in PlasmodiumJalciparum infected erythrocytes. Mol. Biochem. Parasitol. 117(1):37-48.

60. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE. (1994) Order and specificity of the Plasmodium Jalciparum hemoglobin degradation pathway. J. Clin. Invest. 93(4): 1602-8.

61. Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. (2000) Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium Jalciparum. J. BioI. Chem.275(37):29000-10.

137

References

62. Rosenthal PJ, McKerrow JH, Aikawa M, Nagasawa H, Leech JH. (1988) A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodiumfalciparum. J. Clin. Invest. 82(5):1560-6.

63. Dluzewski AR, Rangachari K, Wilson RJ, Gratzer WB. (1986) Plasmodium falciparum: protease inhibitors and inhibition of erythrocyte invasion. Exp. Parasitol. 62(3):416-22.

64. Gamboa de Dominguez ND, Rosenthal PJ. (1996) Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. Blood. 87(10):4448-54.

65. Kamchonwongpaisan S, Samoff E, Meshnick SR. (1997) Identification of hemoglobin degradation products in Plasmodium falciparum. Mol. Biochem. Parasitol. 86(2): 179-86.

66. Asawamahasakda W, Ittarat I, Chang CC, McElroy P, Meshnick SR. (1994) Effects of antimalarials and protease inhibitors on plasmodial hemozoin production. Mol. Biochem. Parasitol. 67(2): 183-91

67. Goldberg DE, Slater AF, Beavis R, Chait B, Cerami A, Henderson GB. (1991) Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173(4):961-9.

68. Barnwell JW, Galinski MR. Invasion of vertebrate cells: erythrocytes. In: Sherman IW (ed.) Malaria: Parasite Biology, Pathogenesis and Protection. Washington DC: ASM, 1998, pp. 93-120.

69. Torii M, Adams JH, Miller LH, Aikawa M. (1989) Release of merozoite dense granules during erythrocyte invasion by Plasmodium knowlesi. Infect. Immun. 57(10):3230-3.

70. Torii M, Aikawa M. Ultrastructure of asexual stages. In: Sherman IW (ed.) Malaria: Parasite Biology, Pathogenesis and Protection. Washington DC: ASM, 1998, pp. 123-134.

71. Sam-Yellowe TY, Shio H, Perkins ME. (1988) Secretion of Plasmodium falciparum rhoptry proteins into the plasma membrane of host erythrocytes. J. Cell BioI. 106(5):1507-13.

72. Banyal HS, Misra GC, Gupta CM, Dutta GP. (1981) Involvement of malarial proteases in the interaction between the parasite and host erythrocyte in Plasmodium knowlesi infections. J. Parasitol. 67(5):623-6.

73. Hadley T, Aikawa M, Miller LH. (1983) Plasmodium knowlesi: studies on invasion of rhesus erythrocytes by merozoites in the presence of protease inhibitors. Exp. Parasitol. 55(3):306-11.

138

ReJerences

74. Dejkriengkraikhul P, Wilairat P. (1983) Requirement of malarial protease in the invasion of human red cells by merozoites of Plasmodium Jalciparum. Z. Parasitenkd. 69(3):313-7.

75. Olaya P, Wasserman M. (1991) Effect of cal pain inhibitors on the invasion of human erythrocytes by the parasite Plasmodium Jalciparum. Biochim. Biophys. Acta. 1096(3):217-21.

76. Breton CB, Blisnick T, Jouin H, Barale JC, Rabilloud T, Langsley G, Pereira da Silva LH. (1992) Plasmodium chabaudi p68 serine protease activity required for merozoite entry into mouse erythrocytes. Proc. Natl. Acad. Sci. USA. 89(20):9647-51.

77. McPherson RA, Donald DR, Sawyer WH, Tilley L. (1993) Proteolytic digestion of band 3 at an external site alters the erythrocyte membrane organisation and may facilitate malarial invasion. Mol. Biochem. Parasitol. 62(2):233-42.

78. Blackman MJ, Holder AA. (1992) Secondary processing of the Plasmodium Jalciparum merozoite surface protein-1 (MSP1) by a calcium­dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP 1. Mol. Biochem. Parasitol. 50(2):307-15.

79. Delplace P, Fortier B, Tronchin G, Dubremetz JF, Vernes A. (1987) Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium Jalciparum. Mol. Biochem. Parasitol. 23(3):193-201.

80. Debrabant A, Delplace P. (1989) Leupeptin alters the proteolytic processing of P126, the major parasitophorous vacuole antigen oj Plasmodium Jalciparum. Mol. Biochem. Parasitol. 33(2): 151-8.

81. Salmon BL, Oksman A, Goldberg DE. (2001) Malaria parasite exit from the host erythrocyte: a two-step process requiring extra-erythrocytic proteolysis. Proc. Natl. Acad. Sci. USA. 98(1):271-6.

82. Greenbaum DC, Baruch A, Grainger M, Bozdech Z, Medzihradszky KF, Engel J, DeRisi J, Holder AA, Bogyo M. (2002) A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science. 298(5600):2002-6.

83. Dua M, Raphael P, Sijwali PS, Rosenthal PJ, Hanspal M. (2001) Recombinant falcipain-2 cleaves erythrocyte membrane ankyrin and protein 4.1. Mol. Biochem. Parasitol. 116(1 ):95-9.

84. Lyon JA, Haynes JD. (1986) PlasmodiumJalciparum antigens synthesized by schizonts and stabilized at the merozoite surface when schizonts mature in the presence of protease inhibitors. J. Immunol. 136(6):2245-51.

139

References

85. Weidekamm E, Wallach DF, Lin PS, Hendricks J. (1973) Erythrocyte membrane alterations due to infection with Plasmodium berghei. Biochirn. Biophys. Acta. 323(4):539-46.

86. Yuthavong Y, Wilairat P, Panijpan B, Potiwan C, Beale GH. (1979) Alterations in membrane proteins of mouse erythrocytes infected with different species and strains of malaria parasites. Cornp Biochern Physiol B.63(1):83-5.

87. Sherman IW, Tanigoshi L. (1983) Purification of Plasmodium lophurae cathepsin D and its effects on erythrocyte membrane proteins. Mol. Biochern. Parasitol. 8(3):207-26.

88. Deguercy A, Hommel M, Schrevel J. (1990) Purification and characterization of 37-kilodalton proteases from Plasmodium falciparum and Plasmodium berghei which cleave erythrocyte cytoskeletal components. Mol. Biochern. Parasitol. 38(2):233-44.

89. Le Bonniec S, Deregnaucourt C, Redeker V, Banerjee R, Grellier P, Goldberg DE, Schrevel J. (1999) Plasmepsin II, an acidic hemoglobinase from the Plasmodium falciparum food vacuole, is active at neutral pH on the host erythrocyte membrane skeleton. J. BioI. Chern. 274(20):14218-23.

90. Storer AC, Menard R. (1994) Catalytic mechanism in papain family of cysteine peptidases. Methods Enzyrnol. 244:486-500.

91. Lecaille F, Kaleta J, Bromme D. (2002) Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chern. Rev. 102(12):4459-88.

92. Wiederanders B. (2000) The function of propeptide domains of cysteine proteinases. Adv. Exp. Med. BioI. 477:261-70.

93. Schilling K, Pietschmann S, Fehn M, Wenz I, Wiederanders B. (2001) Folding incompetence of cathepsin L-like cysteine proteases may be compensated by the highly conserved, domain-building N-terminal extension of the proregion. BioI. Chern. 382(5):859-65.

94. Yamamoto Y, Watabe S, Kageyama T, Takahashi SY. (1999) Proregion of Bombyx mori cysteine proteinase functions as an intramolecular chaperone to promote proper folding of the mature enzyme. Arch. Insect Biochern. Physiol.42(3):167-78.

95. Chapman RL, Kane SE, Erickson AH. (1997) Abnormal glycosylation of procathepsin L due to N-terminal point mutations correlates with failure to sort to lysosomes. J. BioI. Chern. 272(13):8808-16.

140

References

96. Nissler K, Kreusch S, Rommerskirch W, Strubel W, Weber E, Wiederanders B. (1998) Sorting of non-glycosylated human procathepsin S in mammalian cells. BioI. Chem. 379(2):219-24.

97. Fox T, de Miguel E, Mort JS, Storer AC. (1992) Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry. 31(50):12571-6.

98. Carmona E, Dufour E, Plouffe C, Takebe S, Mason P, Mort JS, Menard R. (1996) Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry. 35(25):8149-57.

99. Guo YL, Kurz U, Schultz JE, Lim CC, Wiederanders B, Schilling K. (2000) The alphal/2 helical backbone of the prodomains defines the intrinsic inhibitory specificity in the cathepsin L-like cysteine protease subfamily. FEBS Lett.;469(2-3):203-7.

100. Billington CJ, Mason P, Magny MC, Mort JS. (2000) The slow-binding inhibition of cathepsin K by its propeptide. Biochem. Biophys. Res. Commun.276(3):924-9.

101. McGrath ME. (1999) The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct. 28: 181-204.

102. Karrer KM, Peiffer SL, DiTomas ME. (1993) Two distinct gene subfamilies within the family of cysteine protease genes. Proc. Natl. Acad. Sci. USA. 90(7):3063-7.

103. Wex T, Levy B, Wex H, Bromme D. (1999) Human cathepsins F and W:A new subgroup of cathepsins. Biochem. Biophys. Res. Commun. 259(2):401-7.

104. Wex T, Levy B, Wex H, Bromme D. (2000) Human cathepsins Wand F form a new subgroup of cathepsins that is evolutionary separated from the cathepsin B- and L-like cysteine proteases. Adv. Exp. Med. BioI. 477:271-80.

105. Menard R, Storer AC. (1992) Oxyanion hole interactions in serine and cysteine proteases. BioI. Chem. Hoppe. Seyler. 373(7):393-400.

106. Theodorou LG, Lymperopoulos K, Bieth JG, Papamichael EM. (2001) Insight into the catalysis of hydrolysis of four newly synthesized substrates by papain: a proton inventory study. Biochemistry. 40(13):3996-4004.

107. Schechter I, Berger A. (1967) On the size of the active site in proteases. Biochem. Biophys. Res. Commun. 27(2):157-62.

108. Yamashita DS, Dodds RA. (2000) Cathepsin K and the design of inhibitors of cathepsin K. Curro Pharm. Des. 6(1):1-24.

141

References

109. Engel lC, Doyle PS, Hsieh I, McKerrow lH. (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188(4):725-34.

110. Rosenthal Pl, Kim K, McKerrow lH, Leech lH. (1987) Identification of three stage-specific proteinases of Plasmodium falciparum. J. Exp. Med. 166(3):816-21.

111. Rosenthal Pl, Nelson RG. (1992) Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. Mol. Biochem. Parasitol. 51(1):143-52.

112. Francis SE, Gluzman IY, Oksman A, Banerjee D, Goldberg DE. (1996) Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation. Mol. Biochem. Parasitol. 83(2): 189-200.

113. Salas F, Fichmann l, Lee GK, Scott MD, Rosenthal Pl. (1995) Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect. Immun. 63(6):2120-5.

114. Tyas L, Moon RP, Loetscher H, Dunn BM, Kay l, Ridley RG, Berry C. (1998) Plasmepsins I and II from the malarial parasite Plasmodium falciparum. Adv. Exp. Med. BioI. 436:407-11.

115. Bannister LH. (2001) Looking for the exit: How do malaria parasites escape from red blood cells? Proc. Natl. Acad. Sci. USA. 98(2):383-4.

116. Sijwali PS, Shenai BR, Gut l, Singh A, Rosenthal Pl. (2001) Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem. J. 360(Pt 2):481-9.

117. Francis SE, Banerjee R, Goldberg DE. (1997) Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II. J. BioI. Chem.272(23):14961-8.

118. Rosenthal Pl. (1996) Conservation of key amino acids among the cysteine proteinases of multiple malarial species. Mol. Biochem. Parasitol. 75(2):255-60.

119. Rosenthal Pl. (1993) A Plasmodium vinckei cysteine proteinase shares unique features with its Plasmodium falciparum analogue. Biochim. Biophys. Acta. 1173(1):91-3.

120. Rosenthal Pl, Ring CS, Chen X, Cohen FE. (1994) Characterization of a Plasmodium vivax cysteine proteinase gene identifies uniquely conserved amino acids that may mediate the substrate specificity of malarial hemoglobinases. J. Mol. BioI. 241 (2):312-6.

142

References

121. Knapp B, Nau U, Hundt E, Kupper HA. (1991) A new blood stage antigen of Plasmodium falciparum highly homologous to the serine-stretch protein SERP. Mol. Biochern. Parasitol. 44(1):1-13.

122. Knapp B, Hundt E, Nau U, Kupper HA. (1989) Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch. Mol. Biochern. ParasitoI. 32(1 ):73-83.

123. Li WB, Bzik Dl, Horii T, Inselburg l. (1989) Structure and expression of the Plasmodium falciparum SERA gene. Mol. Biochern. Parasitol. 33(1):13-25.

124. Berti Pl, Storer AC. (1995) Alignment/phylogeny of the papam superfamily of cysteine proteases. J. Mol. BioI. 246(2):273-83.

125. Sabnis Y, Rosenthal Pl, Desai P, Avery MA. (2002) Homology modeling of fa1cipain-2: validation, de novo ligand design and synthesis of novel inhibitors. J. BiornoI. Struct. Dyn. 19(5):765-74.

126. Olson lE, Lee GK, Semenov A, Rosenthal Pl. (1999) Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chern. 7(4):633-8.

127. Rockett KA, Playfair lH, Ashall F, Targett GA, Angliker H, Shaw E. (1990) Inhibition of intraerythrocytic development of Plasmodium falciparum by proteinase inhibitors. FEBS Lett. 259(2):257-9.

128. Rosenthal Pl, Lee GK, Smith RE. (1993) Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest. 91(3):1052-6.

129. McKerrow lH. (1999) Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. 29(6):833-7.

130. Ring CS, Sun E, McKerrow lH, Lee GK, Rosenthal Pl, Kuntz ID, Cohen FE. (1993) Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc. Natl. Acad. Sci. USA. 90(8):3583-7.

131. Li R, Kenyon GL, Cohen FE, Chen X, Gong B, Dominguez IN, Davidson E, Kurzban G, Miller RE, Nuzum EO, et al. (1995) In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chern. 38(26):5031-7.

132. Dominguez IN, Lopez S, Charris l, Iarruso L, Lobo G, Semenov A, Olson lE, Rosenthal Pl. (1997) Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. J. Med. Chern. 40(17):2726-32.

143

References

133. Sabnis VA, Desai PV, Rosenthal PJ, Avery MA. (2003) Probing the structure of fa1cipain-3, a cysteine protease from Plasmodium Jalciparum: comparative protein modeling and docking studies. Protein Sci. 12(3):501-9.

134. Silva AM, Lee A Y, Gulnik SV, Maier P, Collins J, Bhat TN, Collins PJ, Cachau RE, Luker KE, Gluzman IY, Francis SE, Oksman A, Goldberg DE, Erickson JW. (1996) Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium Jalciparum. Proc. Natl. Acad. Sci. USA. 93(19):10034-9.

135. Haque TS, Skillman AG, Lee CE, Habashita H, Gluzman IY, Ewing TJ, Goldberg DE, Kuntz ID, Ellman JA. (1999) Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J. Med. Chern. 42(8): 1428-40.

136. Carroll CD, Johnson TO, Tao S, Lauri G, Orlowski M, Gluzman IY, Goldberg DE, Dolle RE. (1998) Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D. Bioorg Med Chern Lett. 8(22):3203-6.

137. Carroll CD, Patel H, Johnson TO, Guo T, Orlowski M, He ZM, Cavallaro CL, Guo J, Oksman A, Gluzman IY, Connelly J, Chelsky D, Goldberg DE, Dolle RE. (1998) Identification of potent inhibitors of Plasmodium Jalciparum plasmepsin II from an encoded statine combinatorial library. Bioorg. Med. Chern. Lett. 8(17):2315-20.

138. Mayer R, Picard I, Lawton P, Grellier P, Barrault C, Monsigny M, Schrevel J. (1991) Peptide derivatives specific for a Plasmodium Jalciparum proteinase inhibit the human erythrocyte invasion by merozoites. J. Med. Chern. 34(10):3029-35.

139. Vander Jagt DL, Baack BR, Hunsaker LA. (1984) Purification and characterization of an aminopeptidase from Plasmodium Jalciparum. Mol. Biochern. Parasitol. 10(1):45-54.

140. Curley GP, O'Donovan SM, McNally J, Mullally M, O'Hara H, Troy A, O'Callaghan SA, Dalton JP. (1994) Aminopeptidases from Plasmodium Jalciparum, Plasmodium chabaudi chabaudi and Plasmodium berghei. J. Eukaryot. Microbiol. 41 (2): 119-23.

141. Nankya-Kitaka MF, Curley GP, Gavigan CS, Bell A, Dalton JP. (1998) Plasmodium chabaudi chabaudi and P. Jalciparum: inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin. Parasitol. Res. 84(7):552-8.

142. McKerrow JH, Sun E, Rosenthal PJ, Bouvier J. (1993) The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol. 47:821-53.

144

References

143. Tort J, Brindley PJ, Knox D, Wolfe KH, Dalton JP. (1999) Proteinases and associated genes of parasitic helminths. Adv. Parasitol. 43:161-266.

144. Wasilewski MM, Lim KC, Phillips J, McKerrow JH. (1996) Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. Mol. Biochern. Parasitol. 81(2):179-89.

145. Meirelles MN, Juliano L, Carmona E, Silva SG, Costa EM, Murta AC, Scharfstein J. (1992) Inhibitors of the major cysteinyl proteinase (GP57 /51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro. Mol Biochern Parasitol. 52(2): 175-84.

146. Frame MJ, Mottram JC, Coombs GH. (2000) Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology. 121 (Pt 4):367-77.

147. Que X, Reed SL. (2000) Cysteine proteinases and the pathogenesis of amoebiasis. Clin. Microbiol. Rev. 13(2):196-206.

148. Reed SL. (1995) New concepts regarding the pathogenesis of amoebiasis. Clin. Infect. Dis. 21 SuppI2:S182-5.

149. Coombs GH, Denton H, Brown SM, Thong KW. (1997) Biochemistry of the coccidia. Adv. Parasitol. 39:141-226.

150. Ward W, Alvarado L, Rawlings ND, Engel JC, Franklin C, McKerrow JH. (1997) A primitive enzyme for a primitive cell: the protease required for excystation of Giardia. Cell. 89(3):437-44.

151. Lustigman S, McKerrow JH, Shah K, Lui J, Huima T, Hough M, Brotman B. (1996) Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae. J. BioI. Chern. 271(47):30181-9. Erratum in: J. BioI. Chern. (1997) 272(7):4645.

152. Richer JK, Sakanari JA, Frank GR, Grieve RB. (1992) Dirofilaria immitis: proteases produced by third and fourth-stage larvae. Exp. Parasitol. 75(2):213-22.

153. Mckerrow JH. (1994) Proteases as therapeutic targets. Perpect. Drug Discov. Design. 2:437.

154. Carruthers VB, Sherman GD, Sibley LD. (2000) The Toxoplasma adhesive protein MIC2 is proteolytically processed at multiple sites by two parasite­derived proteases. J. BioI. Chern. 275(19):14346-53.

155. Yu D, Wang CC, Wang A. (1995) Maturation of Giardia virus capsid protein involves post translational proteolytic processing by a cysteine protease. J. Virol. 69(5):2825-30.

145

References

156. Caffrey CR, Ruppel A. (1997) Cathepsin B-like activity predominates over cathepsin L-like activity in adult Schistosoma mansoni and S. japonicum. Parasitol. Res. 83(6):632-5.

157. Alexander J, Coombs GH, Mottram Jc. (1998) Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Thl response. J Immunol. 161(12):6794-801.

158. Smith AM, Carmona C, Dowd AJ, McGonigle S, Acosta D, Dalton JP. (1994) Neutralization of the activity of a Fasciola hepatica cathepsin L proteinase by anti-cathepsin L antibodies. Parasite Immunol. 16(6):325-8.

159. Dalton JP, McGonigle S, Rolph TP, Andrews SJ. (1996) Induction of protective immunity in cattle against infection with Fasciola hepatica by vaccination with cathepsin L proteinases and with hemoglobin. Infect. Immun. 64(12):5066-74.

160. Skuce PJ, Redmond DL, Liddell S, Stewart EM, Newlands GF, Smith WD, Knox DP. (1999) Molecular cloning and characterization of gut­derived cysteine proteinases associated with a host protective extract from Haemonchus contortus. Parasitology. 119 (Pt 4):405-12.

161. Jackson EK, Garrison JC. Renin and Angiotensin. In Hardman JG, Limbird LE (eds.). Goodman and Gilman's The pharmacological basis of Therapeutics. New York: McGraw-Hill, 1996. pp.733-758.

162. Deeks SG, Smith M, Holodniy M, Kahn JO. (1997) HIV-l protease inhibitors. A review for clinicians. JAMA. 277(2):145-53.

163. Pierre P, Mellman I. (1998) Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 93(7): 1135-45.

164. Maizels RM, Gomez-Escobar N, Gregory WF, Murray J, Zang X. (2001) Immune evasion genes from filarial nematodes. Int. J. Parasitol.

.. 31 (9):889-98.

165. Kos J, Werle B, Lah T, Brunner N. (2000) Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. BioI. Markers. 15(1):84-9.

166. Kos J, Lah TT. (1998) Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. 5(6):1349-61.

167. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold­O'Donnell E, Salvesen GS, Travis J, Whisstock JC. (2001) The serpins are

146

References

an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. BioI. Chern. 276(36):33293-6.

168. Jacobsen W, Christians U, Benet LZ. (2000) In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab. Dispos. 28(11):1343-51.

169. Marquis RW, Ru Y, Yamashita DS, Oh HJ, Yen J, Thompson SK, Carr TJ, Levy MA, Tomaszek TA, Ijames CF, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, D'Alessio KJ, McQueney MS, Veber DF. (1999) Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg. Med. Chern. 7(4):581-8.

170. Rosenberg AH, Lade BN, Chui DS, Lin SW, Dunn 11, Studier FW. (1987) Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene. 56(1):125-35.

171. Studier FW, Rosenberg AH, Dunn 11, Dubendorff JW. (1990) Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzyrnol. 185:60-89.

172. O'Reilly DR, Miller LK, Luckow VA. (1992) Baculovirus Expression Vectors: a laboratory manual, W.H. Freeman and Co., New York.

173. Kitts PA, Possee RD. (1993) A method for producing recombinant baculovirus expression vectors at high frequency. Biotechniques. 14(5):810-7.

174. Kitts PA, Ayres MD, Possee RD. (1990) Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors. Nucleic Acids Res. 18(19):5667-72.

175. Smith GE, Summers MD, Fraser MJ. (1983) Production of human p interferon in insect cells infected with a baculovirus expression vector. Mol. Cell BioI. 3(12):2156-65.

176. Cereghino JL, Cregg JM. (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24(1):45-66.

177. Clare 11, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA. (1991) High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (NY). 9(5):455-60.

178. Cregg JM, Vedvick TS, Raschke WC. (1993) Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology (NY). 11 (8):905-10.

147

References

179. Roggenkamp R, Janowicz Z, Stanikowski B, Hollenberg CP. (1984) Biosynthesis and regulation of the peroxisomal methanol oxidase from the methylotrophic yeast Hansenula polymorpha. Mol.Gen. Genet. 194(3):489-93.

180. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. (2002) Vaccination of monkeys with recombinant Plasmodiumfalciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 70(12):6961-7.

181. Brady CP, Shimp RL, Miles AP, Whitmore M, Stowers AW. (2001) High­level production and purification of P30P2MSP 1 (19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris. Protein Expr. Purif. 23(3):468-75.

182. Soares IS, Rodrigues MM. (2002) Immunogenic properties of the Plasmodium vivax vaccine candidate MSPl(19) expressed as a secreted non-glycosylated polypeptide from Pichia pastoris. Parasitology. 124(Pt 3):237-46.

183. Goldberg DE, Slater AF, Cerami A, Henderson GB. (1990) Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc. Natl. Acad. Sci. USA. 87(8):2931-5.

184. Trager W., and Jensen, J.B. (1976) Human ma1aria parasite in continuous culture. Science 193: 673-675.

185. Sambrook, J., Fritsch, F. F., Maniatis T. Molecular cloning: A Laboratory manual, 2nd Ed. Cold Spring harbour laboratory Press, 1989.

186. Ellman G. (1959) Tissue sulfhydryl group. Arch. Biochem. Biophys. 82: 70-77.

187. Bohm G, Muhr R, Jaenicke R. (1992) Quantitative analysis of Protein Far­UV circular dichroism spectra by neural networks. Prot. Engg. 5:191-195.

188. Laemmli U.K. (1970) Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 227: 680-685.

189. Towbin H, Staehelin T, Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76(9):4350-4.

190. Matthey B, Engert A, Klimka A, Diehl V, Barth S. (1999) A new series of pET -derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene. 229(1-2):145-53.

191. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM. (1993) A thioredoxin gene fusion expression system that circumvents

148

References

inclusion body formation in the E.coli cytoplasm. Biotechnology (NY). 11(2):187-93.

192. Stewart EJ, Aslund F, Beckwith J. (1998) Disulfide bond formation in the Escherichia coli cytoplasm: an in vivo role reversal for the thioredoxins. EMBO J. 17(19):5543-50.

193. Katakura Y, Zhang W, Zhang G, Omasa T, Kishimoto M, Goto Y, Suga K-I. (1998) Effect of methanol concentration on the production of human /32 glycoprotein-l domain V by a recombinant Pichia pastoris. J. Ferment. Bioeng. 86,482-487.

194. LaLonde JM, Zhao B, Janson CA, D'Alessio KJ, McQueney MS, Orsini MJ, Debouck CM, Smith WW. (1999) The crystal structure of human procathepsin K. Biochemistry. 38(3):862-9.

195. Gardner MJ, Hall N, Fung E, White 0, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. (2002) Genome sequence of the human malaria parasite Plasmodiumfalciparum. Nature. 419(6906):498-511.

196. Rosenthal PJ. (1998) Proteases of malaria parasites: new targets for chemotherapy. Emerg. Infect. Dis. 4(1):49-57.

197. Coulombe R, Grochulski P, Sivaraman J, Menard R, Mort JS, Cygler M. (1996) Structure of human procathepsin L reveals the molecular basis of inhibition by the pro segment. EMBO J. 15:5492-5503.

198. Smith SM, Gottesman, MM. (1989) Activity and deletion analysis of recombinant human cathepsin L expressed in E. coli. J. Bioi. Chern. 264:20487-20495.

199. Nakagawa T, Saito A, Hosaka Y, Ishihara K. (2003) Gingipains as candidate antigens for Porphyromonas gingivalis vaccine. Keio. J. Med. 52(3): 158-62.

200. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Paz M, Villalovos RM, Pompa J. (2003) Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor an interleukin-4. Infect. Immun. 71(7):3844-51.

201. Law RH, Smooker PM, Irving JA, Piedrafita D, Ponting R, Kennedy NJ, Whisstock JC, Pike RN, Spithill TW. (2003) Cloning and expression of the

149

References

major secreted cathepsin B-like protein from juvenile Fasciola hepatica and analysis of immunogenicity following liver fluke infection. Infect. Immun.71(12):6921-32.

202. Gomez-Duarte OG, Lucas B, Van ZX, Panthel K, Haas R, Meyer TF. (1998) Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine. 16(5):460-71.

203. Schnapp AR, Eickhoff CS, Sizemore D, Curtiss R 3rd, Hoft DF. (2002) Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect. Immun. 70(9):5065-74

204. Gor DO, Rosenthal PJ. (1998) Humoral immune response of African to cysteine protease related antigens of Plasmoium falciparum. J. Infect. Dis. 178(1); 285-288.

205. Gor DO, Li AC, Rosenthal PJ. (1998) Protective immune response against protease like antigens of the murine malaria parasite Plasmodium vinckei. Vaccine 16(11-12): 1193-202.

206. Kushwaha A, Rao PP, Suresh RP, Chauhan VS. (2001) Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunol. 23(8):435-44.

207. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Sturchler D. (1999 ) Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 adjuvant. Vaccine. 17(23-24):3145-59.

208. Perlaza BL, Zapata C, Valencia AZ, Hurtado S, Quintero G, Sauzet JP, Brahimi K, Blanc C, Arevalo-Herrera M, Druilhe P, Herrera S. (2003) Immunogenicity and protective efficacy of Plasmodium falciparum liver­stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur. J. Immunol. 33(5):1321-7.

209. Baker SC, Yokomori K, Dong S, Carlisle R, Gorbalenya AE, Koonin EV, Lai MMC. (1993) Identification of the catalytic sites of the papain-like cysteine proteinase of murine coronavirus. J. Virol. 67:6056-6063.

210. Menard R, Carrie J, Laflamme P, et al. (1991) Contribution of the glutamine 19 side chain to transition-state stabilisation in the oxyanion hole of papain. Biochem. 30:8924-8928

211. Vernet T, Berti PJ, Montigny C, et al. (1995) Processing of the papain precursor. J. BioI. Chem. 270: 10838-10846.

150

References

212. E1ce lS, Hegadron C, Gauthier S, Vince lW, Davies PL. (1995) Recombinant calpain II: improved expression systems and production of C105A active-site mutant for crystallography. Prot. Engg. 8:843-848.

213. Loewenthal R, Sancho 1, Fersht AR. (1992) Histidine-aromatic interactions in barnase: Elevation of histidine pKa and contribution to protein stability. J. Mol. BioI. 224:759-770.

214. Sijwali PS, Shenai BR, Rosenthal Pl. (2002) Folding of the Plasmodium Jalciparum cysteine protease falcipain-2 is mediated by a chaperone-like peptide and not the prodomain. J. BioI. Chem. 277(17):14910-5.

215. Rosenthal Pl, Wollish WS, Palmer lT, Rasnick D. (1991) Antimalarial effects of peptide inhibitors of a Plasmodium Jalciparum cysteine proteinase. J. Clin. Invest. 88(5): 1467 -72.

216. liang S, Prigge ST, Wei L, Gao Ye, Hudson TH, Gerena L, Dame lB, Kyle DE. (2001) New class of small nonpeptidyl compounds blocks Plasmodium Jalciparum development in vitro by inhibiting plasmepsins. Antimicrob. Agents Chemother. 45(9):2577-84.

217. Semenov A, Olson lE, Rosenthal Pl. (1998) Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother. 42(9):2254-8.

151